Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
•
Hospital Medicine
How do you manage recurrent C diff which occurs shortly after FMT when alternate etiologies of diarrhea have been excluded and patient is responding to C diff-directed therapies?
Related Questions
Does your hospital or institution have an Antimicrobial Stewardship Program (ASP), which oversees ID physicians, and if so, does the ASP have the authority to refuse an antibiotic prescribed by an ID consultant?
What is your preferred agent and duration to treat an epidural abscess due to azole-resistant candida species?
Do you recommend procalcitonin to help convince other providers to stop antibiotics in patients with pneumonia in whom a non-infectious diagnosis is strongly suspected?
How long would you wait to place a new bone flap for a patient with C. auris skull osteomyelitis associated with cranioplasty s/p bone flap removal, who is currently on anti-fungal therapy?
Do you routinely ask for removal of a indwelling central line (PICC or tunneled catheter) in a patient with pseudomonal bacteremia from known source with otherwise appropriate clinical improvement on anti-pseudomonal antibiotic therapy?
Do you choose an antibiotic with CSF penetration, such as nafcillin over cefazolin, in the setting of MSSA endocarditis with septic emboli to the brain (assuming no concomitant meningitis or brain abscess)?
Would you recommend using a rectal swab for C difficile testing in an inpatient with diarrhea if nurses have been unable to collect a stool sample for 24 hours due to the patient not cooperating with collection?
What workup is sufficient to determine if an aortic aneurysm is "mycotic/infectious" or not, in that you would not prescribe empiric antibiotic therapy?
Do you consider the use of tocilizumab in patients with COVID pneumonia who have had an improvement in supplemental O2 requirements but have significantly elevated inflammatory markers after day two of remdesivir and dexamethasone?
Do you use combination therapy for persistent MSSA bacteremia?
